AstraZeneca defends Crestor
This article was originally published in The Tan Sheet
Executive Summary
A Circulation article linking Crestor (rosuvastatin) to a higher risk of muscle and kidney toxicity compared to other statins is misleading and in "direct contrast" to FDA's position, AstraZeneca says May 23. The study by Alawai Alsheikh-Ali, Tufts-New England Medical Center, et al., "attempts to draw conclusions that simply cannot be drawn from adverse event reporting data," the firm says. The findings were released in May (1"The Tan Sheet" May 30, 2005, p. 6)...